Source: Pharmabiz

Neurocrine Biosciences: Neurocrine Biosciences and Takeda amend strategic collaboration to develop and commercialize osavampator

Neurocrine Biosciences, Inc., is a leading neuroscience─focused, biopharmaceutical company, announced it has amended its agreement with Takeda to develop and commercialize osavampator

Read full article »
Annual Revenue
$1.0-5.0B
Employees
1.0-5.0K
Kyle W. Gano's photo - CEO of Neurocrine Biosciences

CEO

Kyle W. Gano

CEO Approval Rating

85/100

Read more